1-20 of 1035 Search Results for

macular

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Series: ESASO Course Series
Volume: 11
Published: 28 December 2020
10.1159/000485295
EISBN: 978-3-318-06643-2
... Abstract Dry age-related macular degeneration (AMD) is characterized by changes in the outer retina, retinal pigment epithelium (RPE), and choroid. Optical coherence tomography angiography (OCTA) has proven instrumental in analyzing these changes and further understanding the pathogenesis...
Book Chapter
Series: ESASO Course Series
Volume: 11
Published: 28 December 2020
10.1159/000485296
EISBN: 978-3-318-06643-2
... Abstract Age-related macular degeneration (AMD) is the most common cause of central vision loss in developed nations and its prevalence has been progressively increasing over the years. Although many factors have been shown to be involved in AMD pathogenesis, it is well established...
Book Chapter
Series: ESASO Course Series
Volume: 11
Published: 28 December 2020
10.1159/000485299
EISBN: 978-3-318-06643-2
... Abstract Early detection of neovascular age-related macular degeneration is vitally important so that treatment with vascular endothelial growth factor inhibitors can be initiated as soon as symptomatic exudation arises. Swept-source optical coherence tomography angiography (SS-OCTA...
Book Chapter
Series: ESASO Course Series
Volume: 11
Published: 28 December 2020
10.1159/000504906
EISBN: 978-3-318-06643-2
... Abstract Macular telangiectasis encompasses different clinical entities characterized by telangiectatic alterations of the parafoveal retinal capillary plexa involving one or both eyes with different pathogenesis, appearance, and therapeutic response. Diagnosis is mainly based on multimodal...
Book Chapter
Series: ESASO Course Series
Volume: 11
Published: 28 December 2020
10.1159/000504924
EISBN: 978-3-318-06643-2
... Abstract Age-related macular degeneration (AMD) is the leading cause of visual impairment in adults over the age of 55 years in industrialized countries. The intermediate stage of AMD is defined by the presence of large drusen and/or AMD pigmentary abnormalities on funduscopic examination...
Book Chapter
Series: ESASO Course Series
Volume: 9
Published: 07 June 2017
10.1159/000471824
EISBN: 978-3-318-06068-3
... Abstract Age-related macular degeneration (AMD) is one of the main causes of visual deterioration in the developed nations. AMD comes in many forms but the most devastating form is the exudative (wet) type. Over the years, research into the pathophysiology of AMD has led to the discovery...
Book Chapter
Series: ESASO Course Series
Volume: 9
Published: 07 June 2017
10.1159/000471825
EISBN: 978-3-318-06068-3
... Abstract Neovascular age-related macular degeneration (AMD) is a disease with the potential to cause significant visual impairment. The hallmark of this disease is the development of angiogenesis originating from the choroid or retina leading to various, potentially blinding, complications...
Book
Book Cover Image
Series: Developments in Ophthalmology
Volume: 58
Published: 24 April 2017
10.1159/isbn.978-3-318-06033-1
EISBN: 978-3-318-06033-1
Book Chapter
Series: Developments in Ophthalmology
Volume: 58
Published: 24 April 2017
10.1159/000455277
EISBN: 978-3-318-06033-1
... Abstract Diabetic macular edema (DME), defined as a retinal thickening involving or approaching the center of the macula, represents the most common cause of vision loss in patients affected by diabetes mellitus. In the last few years, many diagnostic tools have proven to be useful...
Book Chapter
Series: Developments in Ophthalmology
Volume: 58
Published: 24 April 2017
10.1159/000455279
EISBN: 978-3-318-06033-1
... Abstract Macular edema is one of the most common causes of permanent vision loss in patients with uveitis. The current understanding of water balance and metabolism within the retina has given us better insight into the mechanisms underlying macular edema arising from both acute and chronic...
Book Chapter
Series: Developments in Ophthalmology
Volume: 58
Published: 24 April 2017
10.1159/000455280
EISBN: 978-3-318-06033-1
... Abstract Cystoid macular edema (CME) is a primary cause of reduced vision following both cataract and successful vitreoretinal surgery. The incidence of clinical CME following modern cataract surgery is 0.1-2.35%. Preexisting conditions such as diabetes mellitus and uveitis as well...
Book Chapter
Series: Developments in Ophthalmology
Volume: 58
Published: 24 April 2017
10.1159/000455282
EISBN: 978-3-318-06033-1
... Abstract Macular edema is most often clinically defined as an accumulation of serous fluid within the neurosensory retina with increased thickness of the central retina. In exudative age-related macular degeneration the leakage of fluid from the choroidal new vessels may be the origin...
Book Chapter
Series: Developments in Ophthalmology
Volume: 60
Published: 24 April 2017
10.1159/000460496
EISBN: 978-3-318-06042-3
... Abstract Intravitreal ranibizumab (RBZ) has been shown in multiple randomized clinical trials to be a valuable treatment for diabetic macular edema (DME), promoting a significant improvement in best-corrected visual acuity (BCVA) and in anatomic outcomes. Compared to sham (RISE and RIDE studies...
Book Chapter
Series: Developments in Ophthalmology
Volume: 60
Published: 24 April 2017
10.1159/000460220
EISBN: 978-3-318-06042-3
... Abstract For decades, macular laser photocoagulation has been the standard of care in the treatment of diabetic macular edema (DME). With the relatively recent advent of anti-vascular endothelial growth factor (VEGF) agents, DME treatment has entered a new era. VEGF is a well-known pro...
Book Chapter
Series: Developments in Ophthalmology
Volume: 60
Published: 24 April 2017
10.1159/000459691
EISBN: 978-3-318-06042-3
... Abstract Over the past decade, great strides have been made in the management of diabetic macular edema (DME). Therapeutic alternatives now include focal/grid laser photocoagulation, vitreo-retinal surgery, and intraocular injection of anti-angiogenic and steroid molecules. Intravitreal...
Book Chapter
Series: Developments in Ophthalmology
Volume: 60
Published: 24 April 2017
10.1159/000459692
EISBN: 978-3-318-06042-3
... for the treatment of center-involving diabetic macular edema (DME). A total of 854 adult patients with type I or II diabetes and any level of non-proliferative diabetic retinopathy or proliferative retinopathy with adequate panretinal photocoagulation, with best-corrected visual acuity (BCVA) of 78 to 24 ETDRS...
Book Chapter
Series: Developments in Ophthalmology
Volume: 60
Published: 24 April 2017
10.1159/000459694
EISBN: 978-3-318-06042-3
... comparing aflibercept, bevacizumab, and ranibizumab as treatment option for center-involving diabetic macular edema (DME). The main outcome measures were change in visual acuity (VA), central subfield thickness (CST) on optical coherence tomography, cost effectiveness, burden of care, and safety. Results...